학술논문
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trials
Document Type
Article
Author
Source
In Blood Advances 9 July 2024 8(13):3345-3359
Subject
Language
ISSN
2473-9529